The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
We are pleased to present below all posts archived in 'November, 2016'. If you still can't find what you are looking for, try using the search box.
29 November 2016: London & Oxford, UK - Orchard Therapeutics, a biotechnology company dedicated to bringing transformative ex-vivo gene therapies to patients with serious and life-threatening orphan diseases announces today that it has entered into a strategic alliance with Oxford BioMedica plc, a world-leading company in gene and cell therapy.
Under the terms of the collaboration and licence agreement, Oxford BioMedica has granted an exclusive intellectual property licence to Orchard for collaboration programmes, and will provide process development services and manufacture clinical and commercial GMP-grade lentiviral vectors for Orchard. Oxford BioMedica will receive a 1.95% equity stake in Orchard and will be entitled to royalties on future sales of products covered by the collaboration. The process development arrangements include performance-related incentives, through which Oxford BioMedica could receive a further 1.95% equity stake in Orchard.
The agreement is an important milestone for Orcha ...
Read the rest of entry »
29 November 2016: Gosport, UK - Wickham Laboratories announces the expansion of our service offerings once again within our sterility department. Due to a marked increase in the volume of sterility testing our sterility department has been engaged in over the past year, a refurbishment project was carried out in September to allow space for an additional isolator unit.
The addition of a fourth isolator, scheduled for completion in early 2017, will expand our capacity for testing by over 30% and reduce potential delays in turnaround time. This is the second expansion of our sterility department in the past two years and we are pleased to have the opportunity to continue to provide both our existing and new clients with a high quality sterility testing service they can rely upon.
Company Overview As a GMP/GLP compliant laboratory with over 50 years of experience, Wickham Laboratories Ltd is an established name in the fields of pharmaceutical and medical device contract testing, research an ...
24 November 2016: Abingdon, UK - Human endothelial progenitor cells are a primitive cell type. They are bone marrow derived cells with properties similar to embryonic angioblasts. Progenitor cells migrate into the blood stream and are able to differentiate into a variety of mature vascular endothelial cell types. EPC play an important role in both angiogenesis and vasculogenesis. Compared to specific mature types of endothelial cells such as HMVECs and HUVECs, human EPC are more suitable for cell-based screening of anti-cancer drugs. Endothelial progenitor cells also have an impact on aging and smoking-related diseases, thereby offering beneficial research and drug discovery use in these areas.
17 November 2016: Bridgend, UK & Philadelphia, USA – Bridgend increase followed by expansion at the Rockford Illinois site. The leading pharmaceutical outsourcing services provider PCI Pharma Services (PCI) is extending its current Cryogenic storage capabilities to its Rockford, Illinois operations, complementing the specialised capability currently offered at its Bridgend, UK centre of excellence for Clinical Trial Services.
16 November 2016: Oxford, UK & Marlborough, USA - Oxford Immunotec Global PLC, a global, high-growth diagnostics company focused on developing and commercialising proprietary tests for the management of underserved immune-regulated conditions today announced that it has been included in Deloitte’s 2016 Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. Oxford Immunotec’s US subsidiary was ranked 353rd in the list of 500, based upon Deloitte’s assessment that the Company grew annual revenue 204 percent from fiscal year 2012 to 2015.
16 November 2016: Thame, UK - Horton International, Global Healthcare is pleased to announce that Declan Haverty has joined the UK arm of Horton International, the international Executive Search Organisation, as a Partner, where he will specialise in areas including pharmaceuticals and healthcare as well as IT/technology and business and professional services.
Declan joins us from Informed Decision, a hybrid search practice delivering mid-to-senior level searches internationally for a range of clients across within the healthcare and life sciences arena and beyond, also providing his deep recruitment experience as hands-on interim Head of Recruitment again for a range of clients.
Declan began his career with Price Waterhouse (now PwC) working across business sectors in technology management consultancy with a range of blue-chip corporate clients. After seven years, with experience of professional internal recruitment, he then joined Goodman Graham, a boutique technology search and selection f ...
16 November 2016: Oxford, UK - Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and Clostridium difficile infection, today announces that it has enrolled its first patients at trial sites in the US into PhaseOut DMD, a Phase 2 proof of concept clinical trial of ezutromid in patients with DMD.
15 November 2016: Abingdon, UK - Killer-cell immunoglobulin-like receptors (KIRs), are a family of type I transmembrane glycoproteins expressed on the plasma membrane of Natural Killer (NK) cells and a minority of T cells. They regulate the killing function of these cells by interacting with major histocompatibility (MHC) class I molecules, which are expressed on all nucleated cell types. KIR receptors can distinguish between MHC class I allelic variants, which allows them to detect virally infected cells or transformed cells.
14 November 2016: Bridgend, UK & Philadelphia, USA – Leading pharmaceutical provider PCI Clinical Services, in partnership with Medicon Valley Alliance, will share its expertise at the upcoming Clinical Trial ‘Good Morning’ seminar: “Minimizing Time to Clinic by Maximizing Smart, Efficient Processes” (Copenhagen, November 22). The event will feature presentations from industry experts across a range of topics highlighting innovative practices to supply clinical trial medicines to the investigational sites.
Samantha James, PCI’s Associate Director of Clinical Operations, will present on the topic of FastTrack Packing: Handling Adaptive Clinical Trial Designs and Maximizing Efficiencies. James will discuss the use of advanced methodologies to create greater project flexibility, including FastTrack packaging and Just-in-Time logistical models.
James stated: “As the complexity and competition surrounding clinical trials increases there is a growing need to ...
09 November 2016: St Ives, UK - 2016 has proven to be a phenomenal year of success and growth for the specialist life science recruitment company PiR. Team work, client engagement and an in-depth understanding of the market have resulted in PiR’s most exciting and rewarding year to date, as it continues to work with an outstanding array of companies in the innovative early stage life science space.
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.
Future Blends are looking for an OBN member company who could help them strip solvent from one of their process streams. Initially looking at a 1 tonne scale. If you can help, or know of someone who might be able to then please contact Shane O’Leary at Future Blends. email@example.com.
This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc. Just drop an email to us, firstname.lastname@example.org, and we will post.